跳到正文
原文
Medical Xpress·· 2 天前AI 评分56

研究发现部分BRCA2基因变异与较低的乳腺癌风险相关

Study finds some BRCA2 gene changes carry lower breast cancer risk

AI 导读

梅奥诊所研究团队发表在《自然·通讯》上的一项研究显示,约70种BRCA2低功能(hypomorphic)基因变异携带者的终生乳腺癌风险估算约为20%-25%,低于常见有害BRCA2变异的50%-70%。

正文
mammogram
Credit: CC0 Public Domain

Mayo Clinic researchers, in a study published in Nature Communications, have identified a group of BRCA2 gene variants associated with a moderate risk of breast cancer, a finding that could help health care teams better assess a person's cancer risk and personalize care.

The researchers studied 70 BRCA2 gene variants that they labeled as hypomorphic variants because they only partially disrupt BRCA2 function. They examined how these variants affect the way BRCA2 works and analyzed genetic testing data from a large number of people who had undergone hereditary cancer testing.

Researchers within the study note that individuals who inherit these specific gene changes are estimated to have a 20% to 25% lifetime risk of developing breast cancer. By comparison, people with more common harmful BRCA2 variants may have a 50% to 70% lifetime risk. Because of this reduced risk, these variants are also labeled as reduced penetrance pathogenic variants.

"This shows that not all harmful BRCA2 variants carry the same level of breast cancer risk," says Fergus Couch, Ph.D., a breast cancer researcher at Mayo Clinic Comprehensive Cancer Center. "Understanding these differences could help us better match cancer prevention and screening strategies to an individual's actual risk."

Matching prevention to variant-specific risk

The findings have potential implications for cancer screening and prevention. The researchers note that people who carry these variants may still qualify for and benefit from regular mammograms and breast MRI. However, a more precise understanding of risk could be important when patients and their health care teams consider risk-reducing surgery.

"A small subset of breast cancers are likely caused by BRCA2 hypomorphs," says Couch. "Women and men who inherit these variants should benefit from risk management strategies tailored to the level of risk associated with the specific variant."

Potential response to PARP inhibitors

The researchers also examined whether tumors associated with these variants may be sensitive to PARP inhibitors, a class of targeted cancer drugs that interfere with the ability of cancer cells to repair damaged DNA.

Their findings suggest that some of the tumors associated with hypomorphic BRCA2 variants may respond to PARP inhibitors. Tumor testing may help determine whether this type of treatment is appropriate for an individual patient.

Mapping more inherited risk variants

The researchers are continuing to identify and characterize hypomorphic variants in the BRCA1 and BRCA2 genes associated with inherited breast cancer risk.

"Once the hypomorphic variants are all identified, we will be able to better define risk management and therapeutic strategies for those who carry these variants," Couch says.

The research was conducted in collaboration with investigators from Ambry Genetics.

Publication details

Huaizhi Huang et al., Partially functional hypomorphic missense variants in BRCA2 are reduced penetrance pathogenic variants, Nature Communications (2026). DOI: 10.1038/s41467-026-79433-5

Journal information: Nature Communications

Who's behind this story?

Sadie Harley

Sadie Harley

BSc Life Sciences & Ecology. Microbiology lab background with pharmaceutical news experience in oil, gas, and renewable industries. Full profile →

Andrew Zinin

Andrew Zinin

Master's in physics with research experience. Long-time science news enthusiast. Plays key role in Science X's editorial success. Full profile →

Citation: Study finds some BRCA2 gene changes carry lower breast cancer risk (2026, November 18) retrieved 18 November 2026 from https://medicalxpress.com/news/2026-11-brca2-gene-breast-cancer.html

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

来源:Medical Xpress · medicalxpress.com